pioglitazone has been researched along with Diseases, Metabolic in 8 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Meanwhile, WY-14643 and pioglitazone, 2 drugs widely used for treating metabolic diseases, were employed to prevent oleate-induced disorders of macrophage phospholipid metabolism." | 4.02 | Metabolomics Insights into Oleate-Induced Disorders of Phospholipid Metabolism in Macrophages. ( Ai, XY; Chen, J; Gao, H; Huang, Q; Wu, Z; Yang, BC; Ye, G, 2021) |
| "Pioglitazone did not increase weight or produce any other significant side-effects." | 2.78 | Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. ( Bark, N; Davis, JM; Dwivedi, S; Hu, Q; Jin, H; Li, C; Lohr, J; Mortiere, C; Shekhar, A; Smith, RC, 2013) |
| "Pioglitazone treatment of KK-A(y) mice for 14 days significantly reduced the accumulation of inflammatory cells in ischemic myocardium, and infarct size 3 days after reperfusion compared to vehicle treatment (p<0." | 1.35 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. ( Fuchigami, S; Hayasaki, T; Honda, T; Kaikita, K; Matsukawa, M; Ogawa, H; Sakashita, N; Sugiyama, S; Takeya, M; Tsujita, K, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Colca, JR | 1 |
| Scherer, PE | 1 |
| Ye, G | 1 |
| Yang, BC | 1 |
| Gao, H | 1 |
| Wu, Z | 1 |
| Chen, J | 1 |
| Ai, XY | 1 |
| Huang, Q | 1 |
| Póvoa, VMO | 1 |
| Delafiori, J | 1 |
| Dias-Audibert, FL | 1 |
| de Oliveira, AN | 1 |
| Lopes, ABP | 1 |
| de Paula, EV | 1 |
| Pagnano, KBB | 1 |
| Catharino, RR | 1 |
| Lian, QX | 1 |
| Deng, HZ | 1 |
| Chen, KY | 1 |
| Deng, H | 1 |
| Foryst-Ludwig, A | 1 |
| Clemenz, M | 1 |
| Hohmann, S | 1 |
| Hartge, M | 1 |
| Sprang, C | 1 |
| Frost, N | 1 |
| Krikov, M | 1 |
| Bhanot, S | 1 |
| Barros, R | 1 |
| Morani, A | 1 |
| Gustafsson, JA | 1 |
| Unger, T | 1 |
| Kintscher, U | 1 |
| Finsterer, J | 1 |
| Stöllberger, C | 1 |
| Smith, RC | 1 |
| Jin, H | 1 |
| Li, C | 1 |
| Bark, N | 1 |
| Shekhar, A | 1 |
| Dwivedi, S | 1 |
| Mortiere, C | 1 |
| Lohr, J | 1 |
| Hu, Q | 1 |
| Davis, JM | 1 |
| Honda, T | 1 |
| Kaikita, K | 1 |
| Tsujita, K | 1 |
| Hayasaki, T | 1 |
| Matsukawa, M | 1 |
| Fuchigami, S | 1 |
| Sugiyama, S | 1 |
| Sakashita, N | 1 |
| Ogawa, H | 1 |
| Takeya, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function[NCT00231894] | Phase 4 | 56 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
difference between 2 hr glucose for GTT test at baseline vs after 3 months of drug treatment (NCT00231894)
Timeframe: between baseline and 3 months of study drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | -6.82 |
| Placebo | -40.72 |
difference between 2 hr glucose for GTT test at baseline vs after 3 months of drug treatment (NCT00231894)
Timeframe: between baseline and 3 months of study drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | -24.19 |
| Placebo | 15.19 |
(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | -13.33 |
| Placebo | -11.5 |
(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | 0.02 |
| Placebo | 24.20 |
(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | 6.52 |
| Placebo | 7.72 |
serum high density lipoprotein (HDL) (NCT00231894)
Timeframe: pre-treatment and during 3 months of treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Piogltiazone | 4.62 |
| Placebo | -2.59 |
(NCT00231894)
Timeframe: pre-treatment and during 3 months of treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | -49.65 |
| Placebo | 30.99 |
(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| Pioglitazone | 32.56 |
| Placebo | -79.12 |
The scale is Repeatable Battery for the Assessment to Neuropsychological Status (RBANS). This scale measure cognitive function in patients with schizophrenia. Range for list learning sub-score is 0 to 20 . Higher values indicate better performance. For change score (3 months -baseline) positive values indicate improved performance for this cognitive function and negative values indicate poorer performance on this cognitive function. (NCT00231894)
Timeframe: pre-treatment and 3 months of treatment
| Intervention | Units on RBANS scale (Least Squares Mean) |
|---|---|
| Pioglitazone | 0.27 |
| Placebo | -1.11 |
1 review available for pioglitazone and Diseases, Metabolic
| Article | Year |
|---|---|
The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease.
Topics: Adipose Tissue; Chronic Disease; COVID-19; Diabetes Mellitus, Type 2; Humans; Inflammation; Insulin; | 2022 |
2 trials available for pioglitazone and Diseases, Metabolic
| Article | Year |
|---|---|
Metabolic shift of chronic myeloid leukemia patients under imatinib-pioglitazone regimen and discontinuation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Follow-Up St | 2021 |
Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Antisocial Personality Disorder; Case-Control Stu | 2013 |
5 other studies available for pioglitazone and Diseases, Metabolic
| Article | Year |
|---|---|
Metabolomics Insights into Oleate-Induced Disorders of Phospholipid Metabolism in Macrophages.
Topics: Animals; Chromatography, Liquid; Lipid Metabolism; Macrophages; Mass Spectrometry; Metabolic Disease | 2021 |
Role of Peroxisome Proliferator-Activated Receptor (PPARγ) in Metabolic Disorders in SGA with Catch-Up Growth.
Topics: Adult; Animals; Female; Humans; Infant, Newborn; Infant, Small for Gestational Age; Male; Metabolic | 2018 |
Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma.
Topics: Adipocytes; Animals; Cell Differentiation; Estrogen Receptor beta; Female; Gene Expression; Glucose; | 2008 |
Pioglitazone-induced heart failure in a patient with restrictive cardiomyopathy and metabolic myopathy.
Topics: Cardiomyopathy, Restrictive; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; | 2009 |
Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders.
Topics: Animals; Body Weight; Cells, Cultured; Gene Expression Regulation; Heart Ventricles; Inflammation; M | 2008 |